Clinical Outcomes of Indocyanine Green Tracer Using in Laparoscopic Gastrectomy With Extended Lymphadenectomy Beyond D2 for Locally Advanced Gastric Cancer (FUGES-30)
NCT ID: NCT06945718
Last Updated: 2025-05-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
760 participants
OBSERVATIONAL
2025-05-01
2030-05-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Indocyanine Green Tracer Using in Laparoscopic Gastrectomy With Lymph Node Dissection
NCT03050879
Indocyanine Green Tracer Using in Laparoscopic Radical Gastrectomy for Locally Advanced Gastric Cancer
NCT04593615
Clinical Outcomes of Indocyanine Green Tracer Using in Laparoscopic Gastrectomy With Lymph Node Dissection for Remnant Gastric Cancer
NCT05618821
Indocyanine Green Tracer Using in Laparoscopic Distal Gastrectomy for Early Gastric Cancer
NCT04973475
3D-4K-ICG Laparoscopic Gastrectomy for Gastric Cancer
NCT06161207
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
laparoscopic gastrectomy with beyond D2 regional fluorescent lymph node dissection with ICG group
ICG with D2+ group
beyond D2 regional lymph node dissection
dissect the lymph nodes outside the extent of D2 LN region.
laparoscopic gastrectomy with D2 regional lymph node dissection with ICG group
ICG with D2 group
beyond D2 regional lymph node dissection
dissect the lymph nodes outside the extent of D2 LN region.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
beyond D2 regional lymph node dissection
dissect the lymph nodes outside the extent of D2 LN region.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
Other malignant disease within the past 5 years History of unstable angina or myocardial infarction within past six months History of cerebrovascular accident within past six months History of continuous systematic administration of corticosteroids within one month Requirement for simultaneous surgery for other disease Emergency surgery due to complication (bleeding, obstruction or perforation) caused by gastric cancer FEV1 (forced expiratory volume in one second)\<50% of predicted values Diffuse invasive gastric cancer Tumors preoperatively confirmed to involve the squamocolumnar junction or duodenum History of an iodine allergy Patients who declined laparoscopic surgery
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fujian Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Chang-Ming Huang, Prof.
Chief doctor, phD, FACS
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Chang-Ming Huang, Prof.
Role: PRINCIPAL_INVESTIGATOR
Fujian Medical University Union Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fujian Medical University Union Hospital
Fuzhou, Fujian, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FUGES-30
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.